Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomized, open-label, phase 3 trial - Langdahl, BL; Libanati, C; Crittenden, DB (Lancet, 2017)